Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Exec Vice President and CMO | January 03, 2017 | January 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date January 03, 2017 · Filed January 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,368 |
Ending reported balance
After 2017-01-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-01-03 · Exercise / conversion · Acquired 18,055 · Balance 18,055 F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Row 2 · 2017-01-04 · Sale · Disposed 6,687 · Balance 11,368 F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 162,501 |
Reported balance
After 2017-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-03 · Exercise / conversion · Disposed 18,056 · Balance 162,501 F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.
F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mineralys Therapeutics, Inc.
Report date August 10, 2026 · Filed August 12, 2026
Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,384 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 2,170 · Balance 53,554 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Row 2 · 2026-08-10 · Sale · Disposed 2,170 · Balance 51,384 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2033-02-09 | Direct | 13,024 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 2,170 · Balance 13,024 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 23:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 2,170 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000118 · wk-form4_1786577585.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,024 Underlying: Common Stock · 2,170 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 23:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,170 | $27.09 | $58,785.30 |
DisclosureSEC source: 0001933414-26-000118 · wk-form4_1786577585.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,384 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 23:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 2,170 | $16.00 | $34,720.00 |
DisclosureSEC source: 0001933414-26-000118 · wk-form4_1786577585.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 01:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 416 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001672659-26-000036 · wk-form4_1784595624.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 416 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 01:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 416 | $26.53 | $11,036.48 |
DisclosureSEC source: 0001672659-26-000036 · wk-form4_1784595624.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,384 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 01:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 416 | $15.44 | $6,423.04 |
DisclosureSEC source: 0001672659-26-000036 · wk-form4_1784595624.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 6,349 | $26.61 | $168,954.51 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,384 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · derivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 4,167 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · derivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,167 Underlying: Common Stock · 4,167 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,542 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · derivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,792 Underlying: Common Stock · 3,542 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 14,058 | $27.58 | $387,716.83 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,733 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.965 to $27.750. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 4,167 | $14.25 | $59,379.75 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 13, 2026 Filed Jul 16, 2026 00:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,542 | $10.20 | $36,128.40 |
DisclosureSEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 2,171 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001672659-26-000033 · wk-form4_1783725320.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,194 Underlying: Common Stock · 2,171 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,171 | $30.30 | $65,781.30 |
DisclosureSEC source: 0001672659-26-000033 · wk-form4_1783725320.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,733 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 2,171 | $16.00 | $34,736.00 |
DisclosureSEC source: 0001672659-26-000033 · wk-form4_1783725320.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · balance_after: This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 417 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · derivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 417 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 4,167 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · derivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 4,167 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 4,584 | $25.00 | $114,600.00 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,095 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 417 | $15.44 | $6,438.48 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 4,167 | $14.25 | $59,379.75 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,542 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · derivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,334 Underlying: Common Stock · 3,542 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 9,890 | $23.81 | $235,486.83 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,095 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.41 to $23.98. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,542 | $10.20 | $36,128.40 |
DisclosureSEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| June 12, 2026 Filed Jun 12, 2026 22:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001672659-26-000030 · wk-form4_1781301893.xml · derivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,349 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 12, 2026 Filed Jun 12, 2026 22:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 6,349 | $23.93 | $151,901.09 |
DisclosureSEC source: 0001672659-26-000030 · wk-form4_1781301893.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,443 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.02. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 12, 2026 Filed Jun 12, 2026 22:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001672659-26-000030 · wk-form4_1781301893.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 2,170 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001672659-26-000030 · wk-form4_1781301893.xml · derivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,365 Underlying: Common Stock · 2,170 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,170 | $25.00 | $54,250.00 |
DisclosureSEC source: 0001672659-26-000030 · wk-form4_1781301893.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,443 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 2,170 | $16.00 | $34,720.00 |
DisclosureSEC source: 0001672659-26-000030 · wk-form4_1781301893.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 18, 2026 Filed May 19, 2026 23:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 417 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001933414-26-000086 · wk-form4_1779232505.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 417 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 18, 2026 Filed May 19, 2026 23:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 417 | $27.55 | $11,488.35 |
DisclosureSEC source: 0001933414-26-000086 · wk-form4_1779232505.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,443 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 18, 2026 Filed May 19, 2026 23:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 417 | $15.44 | $6,438.48 |
DisclosureSEC source: 0001933414-26-000086 · wk-form4_1779232505.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 4,166 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · derivative · entry 11 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,501 Underlying: Common Stock · 4,166 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,541 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · derivative · entry 10 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,876 Underlying: Common Stock · 3,541 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 14,056 | $28.58 | $401,789.35 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,443 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.0900 to $29.0208. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 4,166 | $14.25 | $59,365.50 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,541 | $10.20 | $36,118.20 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 12, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · derivative · entry 9 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,698 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 12, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 6,348 | $29.36 | $186,348.08 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,792 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.14 to $29.60. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 12, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 11, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 2,171 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · derivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,535 Underlying: Common Stock · 2,171 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 11, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,171 | $29.71 | $64,500.41 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,792 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| May 11, 2026 Filed May 14, 2026 01:42 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 2,171 | $16.00 | $34,736.00 |
DisclosureSEC source: 0001672659-26-000027 · wk-form4_1778722925.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 416 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001672659-26-000024 · wk-form4_1776812373.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,584 Underlying: Common Stock · 416 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 416 | $31.33 | $13,033.28 |
DisclosureSEC source: 0001672659-26-000024 · wk-form4_1776812373.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,792 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 416 | $15.44 | $6,423.04 |
DisclosureSEC source: 0001672659-26-000024 · wk-form4_1776812373.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 01:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 6,348 | $27.66 | $175,585.68 |
DisclosureSEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,792 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| April 13, 2026 Filed Apr 16, 2026 01:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 4,167 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · derivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,667 Underlying: Common Stock · 4,167 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.